ALLSCHWIL/BASEL, SWITZERLAND - 14 February 2017 - Actelion Ltd (SIX: ATLN) today announced its results for the full year 2016. FINANCIAL HIGHLIGHTS Sales growing to CHF 2,412 million (+15% at CER) Opsumit sales continue strong trajectory and grow to CHF 831 million (+57% at CER) Uptravi sales reach CHF 245 million in first year of launch - driven by the US US GAAP operating income grows to CHF 789 million (+14% at CER) Core operating income grows to CHF 992 million (+17% at CER) USD 30 billion proposal by Johnson & Johnson to acquire Actelion PROPOSED TRANSACTION HIGHLIGHTS Actelion to be acquired by Johnson & Johnson for $ 30 billion with spin-out of new R&D company, listed on Swiss stock...
↧